The Annual Meeting of the Association for Cancer Immunotherapy (CIMT) connects world’s top cancer biology and immunotherapy researchers. This year’s meeting will take place May 10-12, 2022 at the Rheingoldhalle Congress Center in Mainz.
The program includes scientific plenaries covering a wide range of topics including tumor biology, cellular therapy, therapeutic vaccination and immunomonitoring. Sebastian Kreiter, CIMT’s Executive Director Science, and the CIMT Scientific Program Director Mustafa Diken are pleased that a large number of TRON scientists will present their current work at the CIMT poster sessions. Furthermore, David Weber will talk about the EasyFuse platform, recently published in Nature Biotechnogy, which can be used to detect personal gene fusions from RNA-seq data with high accuracy.
The Association for Cancer Immunotherapy CIMT was founded in 2002 by researchers and physicians as an independent non-profit organisation to facilitate the exchange of knowledge between scientists, physicians and regulatory authorities. Based in Mainz, CIMT promotes the development of cancer immunotherapies by, among other things, educating healthcare professionals through annual meetings, educational seminars and publications.
For more information visit the CIMT meeting website.